NEMEJCOVA, Kristyna, Michaela BARTU KENDALL, Romana MICHALKOVA, Jana DROZENOVA, Pavel FABIAN, Oluwole FADARE, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATEJ, Gabor MEHES, Naveena SINGH, Simona STOLNICU, Petr SKAPA, Marian SVAJDLER, Ivana STRUZINSKA, David CIBULA, Roman KOCIAN, Sigurd F. LAX, W Glenn MCCLUGGAGE and Pavel DUNDR. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors. Diagnostic Pathology. LONDON: BMC, 2023, vol. 18, No 1, p. 1-10. ISSN 1746-1596. Available from: https://dx.doi.org/10.1186/s13000-023-01300-4.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors
Authors NEMEJCOVA, Kristyna (203 Czech Republic, guarantor), Michaela BARTU KENDALL (203 Czech Republic), Romana MICHALKOVA (203 Czech Republic), Jana DROZENOVA (203 Czech Republic), Pavel FABIAN (203 Czech Republic), Oluwole FADARE (203 Czech Republic), Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Jan LACO (203 Czech Republic), Radoslav MATEJ (203 Czech Republic), Gabor MEHES, Naveena SINGH, Simona STOLNICU, Petr SKAPA (203 Czech Republic), Marian SVAJDLER (203 Czech Republic), Ivana STRUZINSKA (203 Czech Republic), David CIBULA (203 Czech Republic), Roman KOCIAN (203 Czech Republic), Sigurd F. LAX, W Glenn MCCLUGGAGE and Pavel DUNDR (203 Czech Republic).
Edition Diagnostic Pathology, LONDON, BMC, 2023, 1746-1596.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30109 Pathology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.600 in 2022
RIV identification code RIV/00216224:14110/23:00130742
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1186/s13000-023-01300-4
UT WoS 000926120000002
Keywords in English IMP2; IMP3; Ovarian carcinoma; Immunohistochemistry
Tags 14110230, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 10/5/2023 09:57.
Abstract
BackgroundIMP2 and IMP3 are mRNA binding proteins involved in carcinogenesis. We examined a large cohort of ovarian tumors with the aim to assess the value of IMP2 and IMP3 for differential diagnosis, and to assess their prognostic significance.MethodsImmunohistochemical analyses with antibodies against IMP2 and IMP3 were performed on 554 primary ovarian tumors including 114 high grade serous carcinomas, 100 low grade serous carcinomas, 124 clear cell carcinomas, 54 endometrioid carcinomas, 34 mucinous carcinomas, 75 mucinous borderline tumors, and 41 serous borderline tumors (micropapillary variant). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test.ResultsWe found IMP2 expression (in more than 5% of tumor cells) in nearly all cases of all tumor types, so the prognostic meaning could not be analyzed. The positive IMP3 expression (in more than 5% of tumor cells) was most common in mucinous carcinomas (82%) and mucinous borderline tumors (81%), followed by high grade serous (67%) and clear cell carcinomas (67%). The expression was less frequent in endometrioid carcinomas (39%), low grade serous carcinomas (23%), and micropapillary variant of serous borderline tumors (20%). Prognostic significance of IMP3 could be evaluated only in low grade serous carcinomas in the case of relapse-free survival, where negative cases showed better RFS (p = 0.033).ConclusionConcerning differential diagnosis our results imply that despite the differences in expression in the different ovarian tumor types, the practical value for diagnostic purposes is limited. Contrary to other solid tumors, we did not find prognostic significance of IMP3 in ovarian cancer, with the exception of RFS in low grade serous carcinomas. However, the high expression of IMP2 and IMP3 could be of predictive value in ovarian carcinomas since IMP proteins are potential therapeutical targets.
Links
90125, large research infrastructuresName: BBMRI-CZ III
PrintDisplayed: 6/7/2024 07:59